NewsBenzingaGSK’s Ris-Rez Meets Primary Endpoint In Phase III ARTEMIS-011 Trial, Reducing Risk Of Progression Or Death By 67%, Improving Median Progression-Free Survival To 5.5 Months Vs. 1.4 Months With Chemotherapy In Relapsed Or Refractory Osteosarcoma GSK’s Ris-Rez Meets Primary Endpoint In Phase III ARTEMIS-011 Trial, Reducing Risk Of Progression Or Death By 67%, Improving Median Progression-Free Survival To 5.5 Months Vs. 1.4 Months With Chemotherapy In Relapsed Or Refractory Osteosarcoma Benzinga 2026.10.26 15:34 (GMT+0) Open on Benzinga Other news Citigroup Maintains Buy on Weatherford International, Lowers Price Target to $110 SpaceX Locks Up $40 Billion for AI Chips as Musk Warns Most Neoclouds Will Die Citigroup Maintains Buy on Liberty Energy, Raises Price Target to $28 Landmark Bancorp Declares 5% Stock Dividend Citigroup Maintains Neutral on Netstreit, Lowers Price Target to $18.5 Advance Auto Parts Turnaround Gains Traction, but Analysts Still See Execution Risks
